Bioptimus
Bioptimus, founded by ex-Google DeepMind and Owkin scientists, is building the first universal AI foundation model in biology to drive advancements in scientific research and biotechnological innovation. By employing state-of-the-art AI technologies and accessing unique proprietary data at scale, the company aims to shape the future of scientific research and improve healthcare outcomes globally.
Strategy
Digital Medicine
Status
Live
Website
www.bioptimus.com
Related News
Bioptimus Strengthens Commercial and Scientific Leadership with Key Hires
Bioptimus appoints Julie Gerardi as Chief Commercial Officer
Sofinnova Partners collaborates with NVIDIA to accelerate European life sciences startups
Bioptimus hits $76M funding milestone and prepares to launch groundbreaking foundation model for biology
Bioptimus and Proscia collaborate to accelerate AI innovation in scientific research and drug development for improved patient care
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.